Published in Biomed Chromatogr on June 01, 1986
The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pump. J Cancer Res Clin Oncol (1991) 0.80
The effect of age on the pharmacokinetics of ifosfamide. Br J Clin Pharmacol (1990) 0.79
Pharmacokinetic study of perioperative intravenous Ifosfamide. Int J Surg Oncol (2011) 0.77
Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study. J Cancer Res Clin Oncol (1991) 0.75
Subcutaneous continuous infusion of ifosfamide and cyclophosphamide in ambulatory cancer patients: bioavailability and feasibility. J Cancer Res Clin Oncol (1991) 0.75
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer (2004) 2.87
Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small-cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer (2005) 2.71
Conducting clinical research in the new NHS: the model of cancer. United Kingdom Coordinating Committee on Cancer Research. BMJ (1994) 2.70
Alternate splicing produces a novel cyclin D1 transcript. Oncogene (1995) 2.48
Recombinant human erythropoietin and platinum-based chemotherapy in advanced ovarian cancer. Cancer J Sci Am (2006) 2.42
Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer. Br J Cancer (2000) 2.30
Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer (1987) 2.18
Randomized phase II study of two gemcitabine schedules for patients with impaired performance status (Karnofsky performance status </= 70) and advanced non-small-cell lung cancer. J Clin Oncol (2005) 2.17
Prospective study of follow up alone in stage I teratoma of the testis. Br Med J (Clin Res Ed) (1983) 2.13
Ovarian cancer antigen CA125: a prospective clinical assessment of its role as a tumour marker. Br J Cancer (1984) 2.05
Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer (1987) 1.97
Genetic predisposition to human lung cancer. Br J Cancer (1986) 1.94
A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol (2011) 1.88
Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study. J Clin Oncol (1994) 1.79
Sensitivity and specificity of immunohistochemical markers used in the diagnosis of epithelioid mesothelioma: a detailed systematic analysis using published data. Histopathology (2006) 1.77
Volunteers or victims: patients' views of randomised cancer clinical trials. Br J Cancer (1995) 1.70
The Second Medical Research Council study of prognostic factors in nonseminomatous germ cell tumors. Medical Research Council Testicular Tumour Working Party. J Clin Oncol (1992) 1.67
A randomised clinical trial to contrast radiotherapy with radiotherapy and methotrexate given synchronously in head and neck cancer. Clin Radiol (1987) 1.67
Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma. J Clin Oncol (2003) 1.62
Cancer Research Campaign phase II trial of temozolomide in metastatic melanoma. J Clin Oncol (1995) 1.61
Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol (1998) 1.46
Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial. Blood (1992) 1.45
Expression of epidermal growth factor receptor (EGF-R) in human lung tumours. Br J Cancer (1986) 1.45
2-chlorodeoxyadenosine (2-CDA) therapy in previously untreated patients with follicular stage III-IV non-Hodgkin's lymphoma. Ann Oncol (1996) 1.43
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study. Br J Cancer (2006) 1.41
Carcinosarcoma of the ovary. Br J Cancer (2003) 1.41
A phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br J Cancer (1993) 1.38
Prognostic significance of CCND1 (cyclin D1) overexpression in primary resected non-small-cell lung cancer. Br J Cancer (1996) 1.38
O6-alkylguanine-DNA alkyltransferase depletion and regeneration in human peripheral lymphocytes following dacarbazine and fotemustine. Cancer Res (1991) 1.34
Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst (2000) 1.33
Preclinical development of a vaccine 'against smoking'. Onkologie (2002) 1.33
Comparative pharmacokinetics and alkylating activity of fractionated intravenous and oral ifosfamide in patients with bronchogenic carcinoma. Cancer Res (1989) 1.31
O6-methylguanine-DNA methyltransferase in pretreatment tumour biopsies as a predictor of response to temozolomide in melanoma. Br J Cancer (1998) 1.29
ACTH precursors characterize the ectopic ACTH syndrome. Clin Endocrinol (Oxf) (1994) 1.27
Ifosfamide, etoposide, and thoracic irradiation therapy in 163 patients with unresectable small cell lung cancer. Cancer (1987) 1.26
Prostate stem cell antigen is a promising candidate for immunotherapy of advanced prostate cancer. Cancer Res (2000) 1.24
Predicting septic complications of chemotherapy: an analysis of 382 patients treated for small cell lung cancer without dose reduction after major sepsis. Eur J Cancer (1992) 1.22
Breast cancer: pretreatment drug resistance parameters (GSH-system, ATase, P-glycoprotein) in tumor tissue and their correlation with clinical and prognostic characteristics. Ann Oncol (1997) 1.22
Phase I multicenter study of combined high-dose ifosfamide and doxorubicin in the treatment of advanced sarcomas. Swiss Group for Clinical Research (SAKK). Ann Oncol (1998) 1.20
Chemotherapy for ovarian cancer--a consensus statement on standard practice. Br J Cancer (1998) 1.19
Lymphocyte function and response to chemo-immunotherapy in patients with metastatic melanoma. Br J Cancer (1977) 1.18
Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel. Ann Oncol (2004) 1.17
Human lymphocyte traffic assessed by indium-111 oxine labelling: clinical observations. Clin Exp Immunol (1981) 1.16
Prophylaxis and reversal of ifosfamide encephalopathy with methylene-blue. Lancet (1994) 1.15
A method for following human lymphocyte traffic using indium-111 oxine labelling. Clin Exp Immunol (1981) 1.15
In vitro and in vivo analysis of the effects of recombinant human granulocyte colony-stimulating factor in patients. Br J Cancer (1988) 1.14
Upper abdominal lymphadenopathy as first presentation of relapse, identified by ultrasonography, in patients treated for small cell (oat cell) bronchogenic carcinoma. Br J Dis Chest (1985) 1.14
Remission of diabetes while on sunitinib treatment for renal cell carcinoma. Ann Oncol (2008) 1.10
Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer Prostatic Dis (2005) 1.09
A medical research council randomized trial of single agent carboplatin versus etoposide and cisplatin for advanced metastatic seminoma. MRC Testicular Tumour Working Party. Br J Cancer (2000) 1.08
Viridans streptococcal bacteraemia in patients with haematological and solid malignancies. Eur J Cancer (1991) 1.08
Seroconversion after influenza vaccination in patients with lung cancer. Br J Cancer (1999) 1.08
Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours. Br J Cancer (1999) 1.06
Safety, tolerability and pharmacokinetics of intravenous ghrelin for cancer-related anorexia/cachexia: a randomised, placebo-controlled, double-blind, double-crossover study. Br J Cancer (2008) 1.05
Socio-demographic and medical characteristics of advanced cancer patients using conventional or complementary medicine. Onkologie (2002) 1.05
Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer (2006) 1.05
Melanoma: chemotherapy. Br Med Bull (1995) 1.04
G1 control gene status is frequently altered in resectable non-small cell lung cancer. Int J Cancer (1997) 1.04
Effect of temozolomide on central nervous system relapse in patients with advanced melanoma. Melanoma Res (2002) 1.03
O6-methylguanine formation, repair protein depletion and clinical outcome with a 4 hr schedule of temozolomide in the treatment of advanced melanoma: results of a phase II study. Int J Cancer (2000) 1.03
The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. Curr Drug Targets (2010) 1.03
Three months treatment with chemotherapy and radiotherapy for small cell lung cancer. Br J Cancer (1985) 1.03
Postchemotherapy residual masses in germ cell tumor patients: content, clinical features, and prognosis. Medical Research Council Testicular Tumour Working Party. Cancer (1998) 1.02
Lack of correlation between peripheral blood lymphokine-activated killer (LAK) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2. Int J Cancer (1989) 1.02
Identical chemotherapy schedules given on and off trial protocol in small cell lung cancer: response and survival results. Br J Cancer (2002) 1.02
Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) given as a twice weekly schedule to previously untreated patients with non-small cell lung cancer. Ann Oncol (1994) 1.02
The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. Ann Oncol (2010) 1.01
Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol (1996) 0.99
Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression. Oncogene (1998) 0.99
Rituximab: active treatment of central nervous system involvement by non-Hodgkin's lymphoma? Ann Oncol (2000) 0.98
Immunohistological examination of the inter- and intracellular distribution of O6-alkylguanine DNA-alkyltransferase in human liver and melanoma. Br J Cancer (1992) 0.98
A randomized phase III study comparing dacarbazine, BCNU, cisplatin and tamoxifen with dacarbazine and interferon in advanced melanoma. Br J Cancer (2000) 0.98
The effect of Rituximab on patients with follicular and mantle-cell lymphoma. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol (2000) 0.97
Fighting a losing battle: eating-related distress of men with advanced cancer and their female partners. A mixed-methods study. Palliat Med (2007) 0.97
Inhibition of (mono)amine oxidase activity and prevention of ifosfamide encephalopathy by methylene blue. Drug Metab Dispos (1996) 0.97
A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. Br J Cancer (1996) 0.97
Expression of epidermal growth factor receptor (EGF-R) in non-small cell lung cancer. Use of archival tissue and correlation of EGF-R with histology, tumour size, node status and survival. Br J Cancer (1989) 0.97
Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer (2010) 0.97
Inactivation of O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells by temozolomide. Br J Cancer (1994) 0.97
Expression of the glial glutamate transporter EAAT2 in the human CNS: an immunohistochemical study. Brain Res Mol Brain Res (1997) 0.97
Dosage and cycle effects of dacarbazine (DTIC) and fotemustine on O6-alkylguanine-DNA alkyltransferase in human peripheral blood mononuclear cells. Br J Cancer (1993) 0.96
Radiotherapy for small-cell lung cancer-Where are we heading? Lung Cancer (2008) 0.95
Recombinant human granulocyte macrophage colony stimulating factor (rhGM-CSF) given as daily short infusions--a phase I dose-toxicity study. Br J Cancer (1989) 0.95
Clinical and in vitro effects of recombinant human erythropoietin in patients receiving intensive chemotherapy for small-cell lung cancer. J Clin Oncol (1995) 0.94
High-dose chemotherapy and autologous haematopoietic support in poor risk non-seminomatous germ-cell tumours: an effective first-line therapy with minimal toxicity. Ann Oncol (2000) 0.94
Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. J Clin Oncol (1998) 0.94
Prolongation of ifosfamide elimination half-life in obese patients due to altered drug distribution. Cancer Chemother Pharmacol (1989) 0.94
Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease. J Clin Oncol (1995) 0.94